Company Filing History:
Years Active: 1990
Title: Innovator Spotlight: Gregg A. Tharp
Introduction: Gregg A. Tharp, based in Terre Haute, IN, has made noteworthy contributions to the field of chemistry through his inventive solutions. As a dedicated inventor, Tharp holds one patent that significantly enhances the production of 3-exomethylenecepham sulfoxide esters, showcasing his commitment to advancing chemical processes.
Latest Patents: Tharp's patent, titled "Process for 3-exomethylenecepham sulfoxide esters," offers an innovative method for obtaining these esters in improved yields. The process involves the cyclization of 3-methyl-2-(4-chlorosulfinyl-2-oxo-3-acylamino-1-azetidinyl)-3-butenoic acid esters. This method is conducted under anhydrous conditions using stannic chloride along with various compounds, including ethers, ketones, and unsaturated compounds like alkenes. This patented process is a testament to his expertise and ingenuity in the field.
Career Highlights: Gregg A. Tharp has dedicated his career to working with Eli Lilly and Company, a leading pharmaceutical firm renowned for its commitment to innovation and research. His work is pivotal in developing novel chemical processes that enhance pharmaceutical production and effectiveness.
Collaborations: Tharp has collaborated with industry professionals, including his coworker James Denmore Copp. These partnerships enrich the innovation process, enabling the sharing of knowledge and expertise that leads to groundbreaking developments in the field of chemistry.
Conclusion: Gregg A. Tharp stands out as a visionary inventor whose work in creating improved methods for the synthesis of 3-exomethylenecepham sulfoxide esters demonstrates the vital role of innovation in the pharmaceutical industry. His contributions reflect a dedication to scientific advancement, positioning him as an influential figure within Eli Lilly and Company.